On October 1, Nektar Therapeutics fell 19.63% in regular trading, trading at $48.81 USD/share, with Turnover of $206 million.

Within the Pharmacy sector where Nektar Therapeutics belongs, individual stocks were broadly under pressure. Among individual stocks, Eli Lilly down 0.76%, Johnson & Johnson down 1.96%, Merck down 1.03%, Liquidia Technologies Inc down 11.96%, Pfizer down 1.23%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)